Get the Stockscreener App
108.27
0.46%
-0.50
After Hours:
108.13
-0.14
-0.13%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $108.27, with a volume of 16.54M.
It is down -0.46% in the last 24 hours and down -13.27% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$108.77
Open:
$108.01
24h Volume:
16.54M
Relative Volume:
2.27
Market Cap:
$188.27B
Revenue:
$44.33B
Net Income/Loss:
$6.48B
P/E Ratio:
29.24
EPS:
3.7033
Net Cash Flow:
$6.92B
1W Performance:
-10.62%
1M Performance:
-13.27%
6M Performance:
-14.44%
1Y Performance:
-16.35%
1-Day Range:
$106.96
$109.35
1-Week Range:
$105.78
$122.49
52-Week Range:
$105.78
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories (NYSE:ABT) Finds Support After Recent S&P 500 Decline - Kalkine Media
Abbott: Study shows neuromod systems greatly reduce pain-related healthcare visits - MassDevice
Abbott executive who led TAVR, Tendyne divisions announces exit - Cardiovascular Business
Transcatheter Embolization and Occlusion Devices Market Size to be Valued at USD 11.53 Billion by 2033, Driven by Rising Oncology and Neurovascular Interventions – SNS Insider - GlobeNewswire Inc.
Lbp Am Sa Boosts Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Optimism around Abbott Laboratories (NYSE:ABT) delivering new earnings growth may be shrinking as stock declines 11% this past week - Yahoo Finance
ABT.SW Abbott Laboratories (SIX) CHF100 27 Jan 2026 volume spike: watch momentum - Meyka
Top Executive Makes Bold Move With Major Abbott Laboratories Stock Purchase - TipRanks
Abbott Reworks Nutrition While Targeting Cancer Diagnostics With Exact Sciences Deal - simplywall.st
Ill. Judge Trims False Ad Suit Over Abbott Formula - Law360
Evercore ISI says Abbott’s (ABT) core growth drivers are still intact - MSN
Abbott Laboratories (ABT) Rebounds After Recent Losses - GuruFocus
Abbott Laboratories snaps six straight sessions of losses - MSN
Evercore ISI Says Abbott’s (ABT) Core Growth Drivers Are Still Intact - Insider Monkey
Hedge Fund and Insider Trading News: Ken Griffin, Bill Ackman, Mala Gaonkar, Millennium Management, Berkshire Hathaway, Abbott Laboratories (ABT), GameStop Corp (GME), and More - Insider Monkey
Abbott Eterna Spinal Cord Stimulator Lawsuit Filed Over Lead Migration, Device Malfunction - AboutLawsuits.com
AtaCor Medical Teams Up with Abbott on Defibrillator - ocbj.com
Abbott Laboratories (ABT) CEO Increases Stake with $2M Stock Pur - GuruFocus
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Ford Robert B, Abbott Laboratories chairman, buys $2 million in ABT - Investing.com Nigeria
Ford Robert B buys Abbott shares worth $2m By Investing.com - Investing.com Nigeria
Mutual of America Capital Management LLC Sells 10,889 Shares of Abbott Laboratories $ABT - MarketBeat
3 Reasons to Buy This Dividend King After Its Steep Sell-Off - The Motley Fool
Abbott TAVR leader Chris Waddell is leaving the company - MassDevice
Abbott’s Pōkeno Entry Signals Strategic Nutrition Play - en.edairynews.com
Abbott Laboratories stock faces a Monday test as ABT hovers near a 52-week low - TechStock²
A Look At Abbott Laboratories (ABT) Valuation After Recent Share Price Weakness - simplywall.st
Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy (NYSE:ABT) - Seeking Alpha
Sawgrass Asset Management LLC Trims Stake in Abbott Laboratories $ABT - MarketBeat
Commerzbank Aktiengesellschaft FI Buys 20,825 Shares of Abbott Laboratories $ABT - MarketBeat
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Maravai Lifesciences Holdings (MRVI) and CVRx (CVRX) - The Globe and Mail
Is Abbott's January pullback a good time to buy? - MSN
Is Abbott’s January Pullback a Good Time to Buy? - MarketBeat
Mn Services Vermogensbeheer B.V. Acquires 9,900 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Resona Asset Management Co. Ltd. - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
UniSuper Management Pty Ltd Buys 44,239 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Gibbs Wealth Management - MarketBeat
Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity - Seeking Alpha
Abbott Laboratories (ABT) Margin Compression Challenges Steady Compounder Narrative After FY 2025 Results - simplywall.st
Abbott Laboratories Analyst Cuts Price Target After Q4 Miss, Expects Sales Growth To Accelerate In H2 - Sahm
Earnings snapshot: Abbott Laboratories Q4 beats profit estimates, but misses on revenue; initiates Q1 and FY26 outlook - MSN
Abbott Laboratories (NYSE:ABT) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Assessing Abbott Laboratories (ABT) Valuation After Q4 2025 Earnings Miss And Softer 2026 Guidance - Yahoo Finance
Citigroup Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00 - MarketBeat
Key facts: Abbott Laboratories' stock drops 10.21%; CEO seeks changes; brokers optimistic - TradingView
Abbott India Under Scrutiny Due To Cough Syrup Supply ChainAbbott Laboratories (NYSE:ABT) - Benzinga
Tesla To $360? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Sanford C. Bernstein Lowers Abbott Laboratories (NYSE:ABT) Price Target to $125.00 - MarketBeat
UBS reiterates Buy rating on Abbott Labs stock with $158 price target - Investing.com
Abbott Faces Near-Term Headwinds in Nutrition and Slower Long-Term Libre Growth - Morningstar
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.06%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):